119th Congress · introduced in the House · Oct 17, 2025
Skin Substitute Access and Payment Reform Act
Official title from Congress.gov
Latest action (Oct 17, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
47 citations; showing the 25 most recently posted.
SMITH & NEPHEW, INC. · lobbying firm or registrant: SMITH & NEPHEW, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$480,000
Spent on own lobbying
…e physician fee schedule and Medicare hospital outpatient rule, issues related to skin substitutes. Medicare physician reimbursement for orthopedic procedures. H.R. 5768 / S. 2561, Skin Substitute Access and Payment Act of 2025. Issues related to Medicare coverage for skin substitutes. Issues related to Medicare complexity adju…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF ACCOUNTABLE CARE ORGANIZATIONS · lobbying firm or registrant: NATIONAL ASSOCIATION OF ACCOUNTABLE CARE ORGANIZATIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$177,310
Spent on own lobbying
…H.R. 786/ S. 1460: Preserving Patient Access to Accountable Care Act S. 1816/ 3514: Improving Seniors Timely Access to Care Act S. 1105: No UPCODE Act S. 2561/ H.R. 5768: Skin Substitute Access and Payment Reform Act H.R. 4773/ S.3350: ACO Assignment Improvement Act H.R. 8129: To amend title XVIII of the Social Security Act to…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VENTURE MEDICAL · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$30,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Med…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOWOUND SOLUTIONS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Med…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACESSO BIOLOGICS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Med…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOLAB HOLDINGS, INC. · lobbying firm or registrant: CAPITOL STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
H.R. 5768 - Skin Substitute Access and Payment Reform Act and other skin substitute legislation
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ORGANOGENESIS INC. · lobbying firm or registrant: ORGANOGENESIS INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$24,000
Spent on own lobbying
…ment for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HARBINGER MEDICAL GROUP LLC DBA TIDES MEDICAL · lobbying firm or registrant: THE PICARD GROUP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Medicare/Medicaid
Amount not reported
…Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CONVATEC, INC. F/K/A TRIAD LIFE SCIENCES, INC. · lobbying firm or registrant: HOLLAND & KNIGHT LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 7, 2026 · issue area: Medicare/Medicaid
$30,000
Paid to lobbying firm
S. 2561 / H.R. 5768 - Medicare coverage of wound care therapies; Skin Substitute Access & Payment Reform Act; H.R. 6852 - Advanced Wound Care and Regenerative Medicine Access and…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ADVANCED WOUND THERAPY, LLC · lobbying firm or registrant: PLATINUM ADVISORS DC, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
Support reimbursements for skin substitute products. Support HR. 5768/S. 2561, To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF ACCOUNTABLE CARE ORGANIZATIONS · lobbying firm or registrant: NATIONAL ASSOCIATION OF ACCOUNTABLE CARE ORGANIZATIONS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$142,230
Spent on own lobbying
…H.R. 786/ S. 1460: Preserving Patient Access to Accountable Care Act S. 1816/ 3514: Improving Seniors Timely Access to Care Act S. 1105: No UPCODE Act S. 2561/ H.R. 5768: Skin Substitute Access and Payment Reform Act H.R. 4773/ S.3350: ACO Assignment Improvement Act H.R. 4313/ S.2237: Hospital Inpatient Services Modernization A…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ORGANOGENESIS INC. · lobbying firm or registrant: ORGANOGENESIS INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$33,749
Spent on own lobbying
…ment for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIVEX BIOLOGICS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
…ssues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VENTURE MEDICAL · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$30,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOWOUND SOLUTIONS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACESSO BIOLOGICS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ORGANOGENESIS INC. · lobbying firm or registrant: ARENTFOX SCHIFF LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 19, 2026 · issue area: Medicare/Medicaid
$80,000
Paid to lobbying firm
…s (CY2026 and CY2027) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R.6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act)…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SMITH & NEPHEW, INC. · lobbying firm or registrant: SMITH & NEPHEW, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Medicare/Medicaid
$490,000
Spent on own lobbying
Medicare physician fee schedule and Medicare hospital outpatient rule, issues related to skin substitutes. H.R. 5768 / S. 2561, Skin Substitute Access and Payment Act of 2025. Issues related to Medicare local coverage determinations for skin substitutes. Issues related to APN…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HARBINGER MEDICAL GROUP LLC DBA TIDES MEDICAL · lobbying firm or registrant: THE PICARD GROUP, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 15, 2026 · issue area: Medicare/Medicaid
Amount not reported
…Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers; H.R.5768 Skin Substitute Access and Payment Reform Act; S.2561 Skin Substitute Access and Payment Reform Act; and H.R.6852 Advanced Wound Care and Regenerative Medicine…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
BIOLAB HOLDINGS, INC. · lobbying firm or registrant: CAPITOL STRATEGIES, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 14, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
H.R. 5768 - Skin Substitute Access and Payment Reform Act and other skin substitute legislation
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CONVATEC, INC. F/K/A TRIAD LIFE SCIENCES, INC. · lobbying firm or registrant: HOLLAND & KNIGHT LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 13, 2026 · issue area: Medicare/Medicaid
$90,000
Paid to lobbying firm
S. 2561 / H.R. 5768 - Medicare coverage of wound care therapies; Skin Substitute Access & Payment Reform Act; H.R. 6852 - Advanced Wound Care and Regenerative Medicine Access and…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VENTURE MEDICAL · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$20,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACESSO BIOLOGICS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOWOUND SOLUTIONS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIVEX BIOLOGICS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
…ssues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing